ArticleInternational journal of cancer2026
Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
Persistent infection with high-risk human papillomavirus (HR-HPV) is the necessary cause of cervical cancer, with approximately 95% of cases attributable to eight most carcinogenic HPV types (16/18/31/33/35/45/52/58). Several HPV assays have recently been developed in India for use in cervical cancer screening, including reduced-valency tests targeting seven/eight oncogenic HPV types. We evaluated the clinical accuracy and reproducibility of four such assays: PathoDetect-HPV-14, HPV-Q (14 types), Truenat-HR-HPV-Plus (8 types), and PathoDetect-HPV-7 (7 types). Using the VALGENT framework, 1159 cervical samples from the ESTAMPA study conducted in Argentina and Costa Rica were analysed with the new assays. The samples included 97 cases of CIN2+ (19 CIN2, 72 CIN3, and 6 cancers). Assay performance was compared in a blinded manner with established reference tests (Cobas-4800 and Allplex-HPV-HR) and reduced-valency comparators. Sensitivity, specificity, agreement, and repeatability were assessed. Truenat-HR-HPV-Plus demonstrated a sensitivity of 80.4% (95% CI: 71.1-87.8) and specificity of 91.5% (95% CI: 89.5-93.2) for CIN2+. It met IARC validation criteria and showed non-inferior performance to Allplex-HPV-HR-8, with relative sensitivity of 1.03 (95% CI: 0.96-1.09) for CIN2+ and 1.00 (95% CI: 0.96-1.04) for CIN3+, and relative specificity of 0.99 (95% CI: 0.97-1.00) and 0.98 (95% CI: 0.97-1.00), respectively. Repeatability was 93.3% (κ = 0.79). PathoDetect-HPV-7 showed lower sensitivity (68.1%) with specificity of 89.0%. HPV-Q and PathoDetect-HPV-14 did not meet validation criteria. This study represents the first formal validation of reduced-valency HPV assays and demonstrates that Truenat-HR-HPV-Plus provides robust clinical performance with higher specificity than 14-valent assays, supporting its potential to improve screening efficiency and reduce unnecessary referrals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.